AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Abeona Therapeutics Inc

Healthcare US ABEO

6.75USD
0.0(0.0%)

Last update at 2024-02-22T20:54:00Z

Day Range

6.616.99
LowHigh

52 Week Range

2.195.40
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -39.69600M -84.93600M -84.23400M -76.28200M -56.67100M
Minority interest - - - - -
Net income -31.80900M -88.60600M -88.34900M -76.68200M -56.67100M
Selling general administrative 17.26M 22.80M 23.78M 20.70M 20.11M
Selling and marketing expenses - - - - -
Gross profit 0.96M 3.00M 10.00M -48.56600M 3.00M
Reconciled depreciation 4.58M 3.25M 4.59M 7.82M 2.36M
Ebit -45.25700M -89.83600M -81.42000M -77.09000M -56.66000M
Ebitda -44.68500M -54.05100M -42.61700M -67.20500M -54.30000M
Depreciation and amortization 0.57M 35.78M 38.80M 9.88M 2.36M
Non operating income net other - - - - 1.51M
Operating income -45.25700M -89.83600M -81.42000M -77.09000M -58.16600M
Other operating expenses 46.67M 60.37M 58.50M 77.09M 61.16M
Interest expense 0.74M 3.67M 4.12M 0.40M 0.01M
Tax provision - - - - -
Interest income 0.43M 0.07M 1.30M 1.21M 1.51M
Net interest income -0.30500M -3.60100M -2.81400M 0.81M 1.50M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -7.88700M 3.67M 4.12M 0.40M 1.51M
Total revenue 1.41M 3.00M 10.00M 0.00000M 3.00M
Total operating expenses 46.22M 60.37M 58.50M 77.09M 61.16M
Cost of revenue 0.45M - - 48.57M 38.70M
Total other income expense net 5.56M 4.90M -2.81400M 0.81M 1.50M
Discontinued operations - - - - -
Net income from continuing ops -39.69600M -84.93600M -84.23400M -77.49000M -56.67100M
Net income applicable to common shares -43.47800M -84.93600M -84.23400M -76.28200M -56.67100M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 64.21M 79.59M 151.20M 223.38M 174.40M
Intangible assets - 1.38M 1.50M 36.18M 43.04M
Earning assets - - - - -
Other current assets 0.42M 7.38M 2.71M 3.13M 3.80M
Total liab 37.45M 28.21M 48.65M 44.95M 40.35M
Total stockholder equity 26.76M 51.38M 102.55M 178.43M 134.04M
Deferred long term liab - - - - -
Other current liab 4.20M 10.18M 34.92M 32.94M 3.94M
Common stock 0.18M 1.47M 0.96M 0.84M 0.48M
Capital stock 0.18M 1.47M 0.96M 0.84M 0.48M
Retained earnings -695.33600M -655.64000M -570.70400M -486.47000M -410.18800M
Other liab 23.82M 4.03M - - 20.00M
Good will - 0.00000M 32.47M 32.47M 32.47M
Other assets 0.04M 1.06M 1.14M 1.14M 0.60M
Cash 14.22M 32.94M 12.60M 129.26M 18.75M
Cash and equivalents - - - - -
Total current liabilities 7.78M 16.62M 41.96M 38.70M 20.35M
Current deferred revenue - 0.30M 0.30M 0.30M 0.30M
Net debt -6.59000M -23.56000M -3.86500M -121.30800M 11.25M
Short term debt 1.77M 1.82M 2.04M 1.70M 10.00M
Short long term debt - - 0.33M - 10.00M
Short long term debt total 7.63M 9.38M 8.73M 7.95M 30.00M
Other stockholder equity 722.05M 705.57M 672.30M 664.06M 545.31M
Property plant equipment 11.07M 21.74M 18.35M 13.16M 9.44M
Total current assets 53.10M 55.40M 97.74M 132.39M 88.85M
Long term investments - - - - -
Net tangible assets 26.76M 49.99M 68.58M 178.43M 58.54M
Short term investments 37.93M 12.09M 82.44M 0.00000M 66.22M
Net receivables 0.19M 3.00M - 0.00000M 0.08M
Long term debt - - 1.43M - 20.00M
Inventory 0.34M - - - -
Accounts payable 1.81M 4.33M 4.70M 3.76M 6.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.12900M -0.02700M -0.01000M -4.15700M -1.56000M
Additional paid in capital - - - - -
Common stock total equity - - 0.96M 0.84M 0.48M
Preferred stock total equity - - - - -
Retained earnings total equity - - -570.70400M -486.47000M -410.18800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.04M 1.06M 1.14M 1.14M 0.60M
Deferred long term asset charges - - - - -
Non current assets total 11.12M 24.18M 53.46M 90.99M 85.55M
Capital lease obligations 7.63M 9.38M 6.97M 7.95M -
Long term debt total - - 1.43M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -23.96400M 66.06M -83.71400M 66.48M -65.59200M
Change to liabilities -5.49000M 0.82M -2.17800M -1.70700M 7.96M
Total cashflows from investing activities -23.96400M 66.06M -83.71400M 59.98M -85.08600M
Net borrowings - - 1.76M 1.76M 1.76M
Total cash from financing activities 43.17M 24.86M 1.94M 113.90M 5.48M
Change to operating activities - -16.08800M 3.81M -1.92700M -1.02700M
Net income -39.69600M -84.93600M -84.23400M -76.28200M -56.67100M
Change in cash -24.27400M 25.26M -116.79700M 111.06M -118.72000M
Begin period cash flow 38.83M 13.57M 130.37M 19.31M 138.03M
End period cash flow 14.55M 38.83M 13.57M 130.37M 19.31M
Total cash from operating activities -43.48300M -65.66500M -35.01900M -62.82000M -39.11100M
Issuance of capital stock 69.43M 25.48M 0.00100M 112.93M 0.00000M
Depreciation 4.58M 4.46M 5.60M 8.68M 2.36M
Other cashflows from investing activities - - - -0.19900M -10.25100M
Dividends paid - - - - -
Change to inventory - -16.08100M - -0.08100M -1.02700M
Change to account receivables 3.00M -3.00000M -3.00000M 0.08M 0.03M
Sale purchase of stock -26.25000M - 0.18M 17.93M 5.48M
Other cashflows from financing activities 22.46M -0.62300M 1.94M 0.97M 5.48M
Change to netincome - 33.07M 41.98M 7.34M 7.55M
Capital expenditures 0.13M 4.15M 1.34M 6.51M 19.49M
Change receivables - - - 0.08M 0.03M
Cash flows other operating - - 36.81M -2.63400M -0.33900M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -116.79700M 111.06M -118.72000M
Change in working capital -5.89200M -18.26300M 1.63M -3.55300M 6.96M
Stock based compensation 3.05M 8.92M 8.19M 8.24M 8.87M
Other non cash items -5.52300M -6.55400M 0.88M 0.10M 0.69M
Free cash flow -43.61300M -69.81600M -36.35500M -69.32800M -58.60500M

Fundamentals

  • Previous Close 6.75
  • Market Cap127.33M
  • Volume221731
  • P/E Ratio-
  • Dividend Yield3.82%
  • EBITDA-44.45100M
  • Revenue TTM3.57M
  • Revenue Per Share TTM0.20
  • Gross Profit TTM -28.00100M
  • Diluted EPS TTM-1.37

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABEO
Abeona Therapeutics Inc
0.0 0.0% 6.75 0.0 0.0 32.77 5.31 19.30 -1.6902
NVO
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

Abeona Therapeutics Inc

1330 Avenue of the Americas, New York, NY, United States, 10019

Key Executives

Name Title Year Born
Dr. Vishwas Seshadri M.B.A., Ph.D. Pres, CEO & Director 1976
Dr. Brendan M. O'Malley J.D., Ph.D. Sr. VP & Gen. Counsel 1969
Mr. Joseph Walter Vazzano Chief Financial Officer 1984
Mr. Brian Kevany Ph.D. VP, CTO & Head of Research NA
Mr. Gregory Gin VP of Investor Relations & Corp. Communications NA
Scott Santiamo Director of Corp. Communications NA
Ms. Alison Hardgrove VP of HR NA
Mr. Jon Voss VP & Head of Quality 1960

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).